Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 20/20 | 0.83 |
| ▸ | PKD1 | P98161 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19912127 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL19912052 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL20927177 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL29948039 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL19912135 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL20916219 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL20916215 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL29450144 | 0.91 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL19899426 | 0.86 | MAP3K14 (0.66) | MAP3K14PKD1 | |
| SCHEMBL20927191 | 0.78 | MAP3K14 (0.77) | MAP3K14PKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641894-B | 2-azabicyclo [3.1.0] hex-3-one derivatives and methods of use | 豪夫迈·罗氏有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3504206-B1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-10550117-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | GENENTECH, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550117-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | GENENTECH, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190119274-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119274-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | GENENTECH, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | MAP3K14 1409/4885PKD1 4704/4885 |
| US-10550117-B2 | 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use | NFKB2, NFKBIA, NFKB1 | MAP3K14 858/4885PKD1 2678/4885 |
| US-20190119274-A1 | 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE | NFKB2, NFKBIA, NFKB1 | MAP3K14 858/4885PKD1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.